Can manufacturers add fish oil to canned salmon without affecting taste and texture?
Canned salmon is a staple of the U.S. diet, primarily because of consumer awareness of salmon’s omega-3 content. But no two fish are the same. A salmon’s omega-3 content can vary widely, depending on factors such as sexual maturity and spawning migration (when feeding decreases, salmon use their omega-3s as an energy source). How, then, can manufacturers guarantee the omega-3 content of canned salmon from product to product?
Maybe by adding salmon oil to canned salmon-at just the right amount.
With the help of a USDA grant, researchers from the University of Alaska Fairbanks sought to determine how much salmon oil could be added into canned salmon in such a way that it would guarantee minimum omega-3 contents and not affect consumer tastes. They procured 250 pink salmon (Oncorhynchus gorbuscha) from an Alaskan fishery, classified the fish by their “bright” or “dark” watermarks, and stored them in nearly 1000 cans with 0–4% added salmon oil. After at least eight months, 24 cans were pulled at random and analyzed for omega-3 content. A tasting panel assessed each product for taste, texture, and odor.
Bright pink salmon canned with 2% added fish oil yielded the highest lipid content of any product tested. The lowest lipid content was found in dark pink salmon with 0% added oil. Lipid contents for the other salmon products were deemed comparable, which was likely just due to omega-3 variability in the raw fish.
At the tasting table, volunteers only had disagreement with the taste and texture of dark pink salmon at 4% added oil, so the researchers offered final recommendations of 1% oil for canned bright pink salmon and 2% oil for canned dark pink salmon. These additions should guarantee minimum omega-3 contents of 1.9 g and 1.5 g per 100 g, respectively, noted the researchers.
Recent animal study finds that Lysoveta may help reduce neonatal brain injury
July 17th 2024A recent animal study found that lysophosphatidylcholine (LPC)-bound omega-3 long-chain polyunsaturated fatty acids (LCPUFAs), marketed as Lysoveta by Aker BioMarine, protected against neonatal hypoxic-ischemic (HI) brain injury in mice.
Krill oil supplementation raises Omega-3 Index of Lupus patients in recent study
July 16th 2024The study was conducted at 20 research centers in the United States by Aker BioMarine and the Lupus Clinical Investigators Network with oversight by Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance.
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.
Recent review states that pentadecanoic acid may support cellular stability for better longevity
June 25th 2024According to the paper’s author, Stephanie Venn-Watson, DVM, MPH, deficiency in pentadecanoic acid of ≤0.2% total circulating fatty acids increases the risk of ferroptosis, which a type of cell death cause by the peroxidation of fragile fatty acids in cell membranes that combines with iron thus increasing reactive oxygen species, and disabling mitochondria.